SEC Form 10-Q filed by Repare Therapeutics Inc.
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/9/2023 | $11.00 → $16.00 | Hold → Buy | Stifel |
2/3/2023 | $28.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
1/6/2023 | $28.00 | Overweight | CapitalOne |
4/12/2022 | $11.00 | Buy → Hold | Stifel |
3/17/2022 | $43.00 | Buy | Goldman |
9/23/2021 | $48.00 | Buy | Stifel |
9/13/2021 | $54.00 | Buy | HC Wainwright & Co. |
8/16/2021 | $45.00 → $47.00 | Overweight | Morgan Stanley |
Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). Repare also announced its intention to seek partnering opp
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroug
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte
Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously
Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously
CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)
Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, May 31, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)